Kevin Barber, MS, PhD, RAC, PMP is Vice President of Regulatory Affairs and leads the development and execution of Novan’s regulatory strategy. Dr. Barber has over 21 years of experience in pharmaceutical product development and biomedical research with a background in designing and implementing effective integrated regulatory plans. Most recently, Dr. Barber served as Vice President of Global Brand Regulatory Affairs at Actavis (formerly Watson Pharmaceuticals) where he was responsible for regulatory development of over 20 products and regulatory life cycle management of more than 150 approved products in US, Canadian, and European markets.
William L. Hodges, CPA, is the interim Chief Financial Officer. Most recently, Mr. Hodges was chief financial officer and senior vice president of finance and administration for POZEN, Inc., where he was part of the team that led to the development and commercialization of Vimovo®, Treximet® and Yosprala™. In February 2016, POZEN completed the acquisition of Tribute Pharmaceuticals Canada Inc. along with a $350 million commitment from leading healthcare capital partners to form a premier specialty pharmaceutical company, Aralez Pharmaceuticals Inc. Previously, Mr. Hodges held numerous, progressive roles in finance including vice president, corporate planning and business support, at GlaxoWellcome before being appointed acting senior vice president and chief financial officer for the fifteen months leading up to the GlaxoSmithKline merger in 2000.
Stan Hollenbach, BS, JD, is the Senior Vice President of Research and Development and leads all phases of pharmaceutical drug development other than clinical testing of Novan’s product candidates. Mr. Hollenbach has more than 25 years of experience in the biotechnology industry specializing in preclinical development of small molecules and proteins which included participation in numerous US and European regulatory submissions. Prior to joining Novan in 2014, Mr. Hollenbach was the vice president of pharmacology at Portola Pharmaceuticals, Inc., where he focused primarily on platelet and fibrin mediated thrombosis, leading the preclinical development of orally bioavailable antiplatelet P2Y12 antagonists and the factor Xa inhibitors andexanet alpha and betrixaban. He also worked previously at COR Therapeutics which was acquired by Millennium Pharmaceuticals and Genetech as well as served in the US Army at the Letterman Army Institute of Research (LAIR) with research experience in emergency care and resuscitative therapy of combat casualties.
Jeff N. Hunter, MS, is the Vice President of Technical Operations and has been integral to the company’s execution and operational success since its inception. With more than 30 years of broad business experience including as co-founder and former CEO and Chairman of a small-cap public company, Mr. Hunter has built Novan’s corporate infrastructure systems as well as strengthened supply chain and business relationships. His versatility and in-depth understanding of the company’s business encompass manufacturing and product development. In 2013, the Triangle Business Journal recognized Mr. Hunter as a top executive in his field. In 2015, he was appointed to serve on the Board of Directors of the North Carolina Biotechnology Center.
Brian Johnson is the Chief Commercial Officer responsible for Novan’s commercialization efforts including sales, marketing and managed care for the company’s dermatology products. Mr. Johnson brings to Novan nearly three decades of marketing and sales leadership at dermatology companies including Ortho Pharmaceutical Corporation (Johnson & Johnson’s Dermatological Division), Medicis Pharmaceutical Corporation and Galderma Laboratories, LLC where he served as Vice President of Prescription Marketing and Chief Digital Officer. At Galderma, he and his team quadrupled sales by launching category leaders like Epiduo®, Clobex® and Oracea®. In addition to Epiduo®, he participated in the sales and/or marketing of other leading acne brands including Retin-A®, Dynacin®, and Differin®.
Tim O’Sullivan, JD, MBA, is the Vice President of Intellectual Capital and spearheads the strategic development of the Company’s intellectual property portfolio. He manages Novan’s licensing strategy and is responsible for building the Company’s robust barriers to entry. Mr. O’Sullivan has more than 20 years of experience in developing intellectual property portfolios. Before joining Novan, Mr. O’Sullivan was the Director of Intellectual Property and Business Development for LED Lighting Solutions at Cree, Inc.
Paula Brown Stafford, MPH, is the Chief Development Officer and leads the tactical execution of clinical trials and the establishment of statistics and data management functions for Novan. Most recently, Ms. Stafford served as president of clinical development at Quintiles (now QuintilesIMS), where she was responsible for all Phase I-IV clinical development operations globally, reaching $3 billion in annual revenue. During her time at Quintiles, Ms. Stafford was also a member of the Quintiles executive committee for more than five years and founded Quintiles Enterprise Data Council and Quintiles Women Inspired Network. Ms. Stafford serves as a director at Health Decisions, Inc. and adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at The University of North Carolina at Chapel Hill. Additionally, she provides executive solutions and coaching through her consulting firm, Habergeon LLC. Ms. Stafford was a 2011 recipient of the Triangle Business Journal’s Women in Business award and named as one of the 10 top women in biotech by FierceBiotech in 2012.
Nathan Stasko, PhD, is co-founder, President and Chief Executive Officer and a Director of Novan, Inc. Dr. Stasko has led the transformation of the Company’s nitric oxide platform from the academic benchtop to Phase 3 clinical trials and is considered a leading expert in the field of nitric oxide. He is an inventor of the core Novan technology and of more than 100 patent filings, 19 of which have issued, and has authored several peer-reviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide. Dr. Stasko has led the Company through each of its private financings totaling more than $100 million, as well as the award of government grants and contracts totaling $15 million, the latter ultimately resulting in Novan’s national recognition as a Tibbetts Award winner for excellence in Small Business Innovation Research. He has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise, who share his vision to position Novan as a commercially successful leader in the dermatology market.